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Abstract
Introduction
This study explores factors associated with virological detectability, and viral re-suppression
after enhanced adherence counselling, in adults and children on antiretroviral therapy
(ART) in Swaziland.
Methods
This descriptive study used laboratory data from 7/5/2012 to 30/9/2013, which were linked
with the national ART database to provide information on time on ART and CD4 count; infor-
mation on enhanced adherence counselling was obtained from file review in health facili-
ties. Multivariable logistic regression was used to explore the relationship between viral
load, gender, age, time on ART, CD4 count and receiving (or not receiving) enhanced
adherence counselling.
Results
From 12,063 patients undergoing routine viral load monitoring, 1941 (16%) had detectable
viral loads. Children were more likely to have detectable viral loads (AOR 2.6, 95%CI
1.5–4.5), as were adolescents (AOR 3.2, 95%CI 2.2–4.8), patients with last
CD4<350 cells/µl (AOR 2.2, 95%CI 1.7–2.9) or WHO Stage 3/4 disease (AOR 1.3, 95%CI
1.1–1.6), and patients on ART for longer (AOR 1.1, 95%CI 1.1–1.2). At retesting, 450 (54%
of those tested) showed viral re-suppression. Children were less likely to re-suppress
(AOR 0.2, 95%CI 0.1–0.7), as were adolescents (AOR 0.3, 95%CI 0.2–0.8), those with initial
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viral load> 1000 copies/ml (AOR 0.3, 95%CI 0.1–0.7), and those with last CD4<350 cells/µl
(AOR 0.4, 95%CI 0.2–0.7). Receiving (or not receiving) enhanced adherence counselling
was not associated with likelihood of re-suppression.
Conclusions
Children, adolescents and those with advanced disease were most likely to have high viral
loads and least likely to achieve viral suppression at retesting; receiving adherence coun-
selling was not associated with higher likelihood of viral suppression. Although the level of
viral resistance was not quantified, this study suggests the need for ART treatment
support that addresses the adherence problems of younger people; and to define the ele-
ments of optimal enhanced adherence support for patients of all ages with detectable viral
loads.
Introduction
In 2013 the World Health Organisation (WHO) recommended routine annual viral load (VL)
monitoring for all patients on antiretroviral therapy (ART), as the most accurate available mea-
sure of effective treatment response.[1] An elevated or ‘non-suppressed’ VL (>1000 copies/ml)
in a patient who has been on ART for at least six months can indicate either therapeutic failure
due to antiretroviral resistance, and / or poor adherence to treatment. To distinguish between
these two conditions, a patient with an elevated VL should receive adherence support followed
by retesting three to six months later.[1] According to the WHO guidelines, patients whose
VLs are not suppressed at retesting can be classified as having ‘virologic failure’ due to probable
drug resistance, and should be switched to second line therapy.[1]
Previous studies on VL monitoring suggest a number of factors that may be associated with
having an elevated VL, and subsequent virologic failure. Patients on treatment for more than
one year are more likely to have virologic failure and to have resistance mutations.[2] Children
are also more likely to have persistently elevated VLs despite adherence support.[3] However,
children and adolescents often have challenging adherence problems, related to inadequate
drug formulations, social context (e.g. lack of consistent care-giver in younger children) and
psycho-developmental stage (e.g. disclosure and acceptance of diagnosis in adolescents), which
may not respond to conventional forms of adherence support.[4] Young people may therefore
fail to achieve viral re-suppression following adherence counselling, without necessarily having
resistant virus.[5] If indeed adherence counselling is not meeting the specific adherence-related
needs of children, using the WHO 2013 algorithm could result in over-estimation of virologic
failure due to resistance in younger people, resulting in inappropriate switches to second line
therapy.
Swaziland has the highest prevalence of Human Immunodeficiency Virus (HIV) of any
country worldwide (31% amongst the 18–49 age group), and in 2012 introduced routine VL
monitoring for patients on ART as a pilot programme in the Shiselweni region.[6–7] The
implementation challenges of VL monitoring in this setting have been described previously,
yet there have been no published analyses of predictors of virological outcomes in Swaziland.
[5] Identification of predictors of virological failure is important for health programmers since
it can enable better targeting of adherence support. Although previous studies in sub-Saharan
Africa have addressed this question, it is difficult to generalise these findings to Swaziland
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which has a relatively new ART programme and has lower levels of HIV drug resistance than
other countries in the region.[ 8, 9] Furthermore, around 10% of the ART cohort in Swaziland
are under the age of 20, which enables a robust description of virological outcomes in younger
people in a sub-Saharan setting.[7] This analysis of factors associated with viral suppression in
Swaziland thus aims to identify groups at risk of having non-suppressed VL and hence virolog-
ic failure, to enable better targeting of adherence support and referral for clinician review.
Objectives
This primary objective of this study is to explore factors associated with virological detectabili-
ty, and subsequent virologic failure in adults and children on ART in Swaziland. The secondary
objective is to establish whether receiving enhanced adherence counselling is associated with
likelihood of viral re-suppression, amongst patients with initial detectable VL.
Methods
Design
This was a descriptive study using routinely collected programme data.
Setting
Swaziland is a landlocked, lower-middle income country in Southern Africa, with a population
of 1.2 million and an adult HIV prevalence of 31%.[1] The study region (Shiselweni) has a
largely rural population of 210,000, with an estimated 37,000 people living with HIV, of whom
16,349 were on ART at the end of 2012.[2] ART is provided from 22 primary care clinics and
three referral facilities.
In May 2012, Médecins Sans Frontières (MSF) and the Ministry of Health of Swaziland
implemented routine VL monitoring in Shiselweni, with enhanced adherence counselling
(EAC) for patients with detectable VL, using a generic HIV VL platform commercialised by
Biocentric (Bandol, France). In Shiselweni, patients on ART now undergo annual VL testing
once they have been on ART for six months (as a measure of early adherence), and annually
thereafter. Patients with detectable VLs are referred to a lay-counsellor for three months’ EAC
followed by retesting the following month, at which point they are referred to a doctor if their
VL remains elevated. Full details of the programme and VL monitoring algorithm have been
published previously.[5]
Participants and data collection
All patients undergoing VL testing in health facilities in Shiselweni between 7/5/2012 and
30/9/2013 were included in the analysis. VL laboratory records included information on test
results and dates, age, sex and health facility. Laboratory records from all patients who under-
went VL monitoring in this period were linked to the national ART database (APMR) using a
unique patient identifier (ART number) to provide information on time on ART, recent CD4
count, recent WHO clinical stage, ART regimen and TB co-infection status. WHO staging and
recent CD4 data were only considered relevant if the CD4 or WHO clinical stage had been
taken within 12 months of the VL test date. If no CD4 or VL had been recorded within the last
12 months, these variables were coded as missing.
Trained data clerks visited the health facilities to review a consecutive sample of 200 patient
files of patients with detectable VLs from 1st Oct 2012 to 31st March 2013, and recorded the
dates of the counselling sessions following a detectable VL.
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Analysis
Two separate analyses were conducted based on two binary outcome variables:
• For the analysis of predictors of viral detectability, the outcome variable was “Initial VL”,
classified as “detectable” or “undetectable” according to the detection threshold of the Bio-
centric technique (100copies/ml).
• For the analysis of predictors of virologic failure, the outcome variable was “Follow-up VL”,
classified as “re-suppressed” or “virologic failure”, with viral re-suppression defined as unde-
tectable VL (less than 100copies/ml), or a 2 log reduction in VL, at least 60 days after an ini-
tial detectable VL.
In view of the possibility of virological blips between 100 and 1000 copies/ml, this analysis
was re-run excluding the group with a first VL in this range to ascertain whether this altered
the findings.
Explanatory variables used in the analysis were gender, age, type of facility (primary or
secondary health care), time on ART, last WHO clinical stage, last CD4 count, treatment
regimen (1st or 2nd line) and TB co-infection status. For the analysis of factors associated with
viral re-suppression, initial VL and number of EAC sessions received were also included as ex-
planatory variables. Time on ART was treated as a continuous variable; patients were also cate-
gorised as having been on ART for more or less than nine months, in view of the clinical
relevance of distinguishing between patients undergoing VL monitoring as a test of early
adherence at six months since initiating ART, and those undergoing routine annual
monitoring.
Pearson’s Chi Square test was used to compare categorical variables, and the Kruskal-Wallis
test was used for comparison of medians for continuous variables with asymmetric distribu-
tions. Multivariable logistic regression [reported with Adjusted Odds Ratios (AOR) with 95%
Confidence Intervals (95% CI)] was performed in a backward, step-wise manner, from an ini-
tial model which included all explanatory variables with a p-value of<0.1 on bivariate analysis,
until a best-fit model was found. Data entry was carried out with EpiData 3.1, and data analysis
was performed using Stata/SE (StataCorp, Texas, U.S.A.) Version 12.1.
Since the study was carried out using only routine data sources, there was a substantial
proportion of missing data. For each variable of interest, we assessed whether having a missing
value was associated with the outcome of interest (detectability or re-suppression) and wheth-
er the missing values were disproportionately distributed among certain groups (such as in
specific health facilities). Many patients with missing values came from the same few health
facilities, so clustering by health facility was controlled for in the analysis. In the final model
regression models, analysis was restricted to records for which all relevant variables were
available. This decision was made after exploring the potential impact on the findings of in-
cluding these extra records in the analysis (see S1 Table and ‘missing data’ in the discussion
below).
Ethics
This study has received ethical approval from the MSF Ethics Review Board, Geneva, Switzer-
land, and the Swaziland Scientific and Ethics Committee, Mbabane, Swaziland. Since this study
uses only laboratory records and information from routine clinical records, patients were not
asked to give written consent for study participation. To protect patient confidentiality, all rec-
ords were anonymised and de-identified prior to analysis.
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Results
Patient characteristics and exclusions
Fig. 1 summarises the inclusions and exclusions for the different stages of the analysis. Of 15,497
VL laboratory records from tests ordered between 7/5/2012–30/9/2013, 2151 were excluded
since the patient had already had an annual test in the study period, and 1283 were excluded
because they had no unique identifier recorded (thus it was unclear if the test was a routine or
follow-up test). The 12,063 identifiable patients who underwent VL monitoring over this period
represent 73% of the Shiselweni ART cohort of 16,349 patients, and all were included in the “Pre-
dictors of viral detectability” analysis. There was no difference in the proportion of detectable
results amongst those patients that were included and those that were excluded from the study.
Many patient records had missing data for some of the explanatory variables of interest. We
were able to link the laboratory records with the national ART database for 9954 (83%) of the
patients. For those patient records that could not be linked, information could thus not be ob-
tained on time on ART, CD4, WHO stage, TB status and ART regimen; these patients were
more likely to have detectable VLs (see discussion and S1 Table). Amongst those records that
could be linked, a number of CD4 results (5692) and WHO staging results (205) were excluded
since they were obtained more than 12 months prior to the VL test. There was no difference in
the proportion of detectable VLs amongst patients whose CD4 and WHO staging results were
excluded, and the rest of the cohort.
Characteristics of patients at time of VL testing are shown in Tables 1 and 2, and the data is
provided in S1 and S2 Datasets (although unique patient identifiers have been removed). From
the full sample of 12,063 patients, 4220 (35%) were male and 1,168 (10%) were under the age of
20. For patients with available data, median time on ART was 2.7 years; and 66 (0.7%) were on
second line therapy. Of those patients with CD4 andWHO staging information recorded in the
last 12 months, 1421 (45%) had a CD4<350 cells/ml, and 2682 (28%) were WHO stage 3 or 4.
Factors associated with having a detectable VL
On bivariate analysis, males, patients under 20 yrs old, those with WHO stages 3 or 4 disease
or advanced immuno-suppression (CD4<350 cells/ml), and those managed in primary rather
than secondary care locations, were more likely to have detectable VL (p<0.001 in all cases).
Patients with detectable VL tended to have been on ART for longer than patients with unde-
tectable VL, although this was not statistically significant (p = 0.08). ART regimen and TB co-
infection status were not associated with virological detectability. Patients undergoing VL
testing for early adherence (at six months) were no more likely to have a detectable VL than
patients attending for routine annual monitoring.
In the final adjusted model, the key predictors of detectability were: being an adolescent or a
child, longer time on ART, WHO Clinical Stages 3 and 4, and recent CD4<350 cells/ml. Crude
and Adjusted Odds Ratios are shown in Table 1.
Factors associated with virologic failure and re-suppression
Of the original 12,063 patients, 1,930 (16%) had a detectable VL, of whom 835 had a follow-up
VL during the study period; this represents approximately 60% of those eligible for follow-up
testing during the study period, on the basis of the timing of their first test. The median time to
follow-up was four months. All 835 patients with a follow-up VL test were included in the “pre-
dictors of virologic failure” analysis, of whom 451 (54%) showed viral suppression at re-testing.
Again, not all patients had complete data for all explanatory variables of interest, but no patient
was excluded on this basis.
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Figure 1. Numbers and proportions of viral load tests included and excluded at each stage of the analysis of predictors of virological outcomes,
Swaziland, 2012–2013.
doi:10.1371/journal.pone.0116144.g001
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The review of 200 patient files to obtain information on EAC yielded 180 files with informa-
tion recorded: 35 (19%) had received no EAC; 145 (81%) had received at least one session of
counselling, and 36 (20%) had received all three sessions. In 20 files it was unclear whether the
patient had received EAC or not. There was no difference in the rates of re-suppression among
the sample of 180 patients for whom information on EAC was collected, and the rest of the
cohort.
Table 1. Factors associated with detectable viral load (viral load >100 copies/ml) in patients on antiretroviral therapy for more than six months
in Swaziland, 2012–2013.
Total n Detectable n (%) Odds Ratio OR (95% CI) Adj Odds Ratio1 OR (95% CI)
Gender
Male 4220 (100%) 742 (18) 1.2 (1.1–1.3)
Female 7824 (100%) 1196 (15) 1
Age group
<10yrs (children) 580 (100%) 170 (29) 2.5 (2.1–3.0) 2.6 (1.5–4.5)
10–19yrs (adolescents) 588 (100%) 207 (35) 3.2 (2.7–3.9) 3.2 (2.2–4.8)
20+ (adults) 10808 (100%) 1553 (14) 1 1
Type of facility
Secondary facility 6267 (100%) 938 (15) 1.2 (1.1–1.3)
Primary care clinic 5796 (100%) 1003 (17) 1
Time on ART2
Median time in years(IQR) 2.7 (1.4–4.4) 2.8(1.5–4.6)3 1.0 (1.0–1.1) 1.1 (1.1–1.2)
< 9 months (early adherence) 922 130 (14) 0.9 (0.7–1.1)
> 9 months (routine annual) 8985 1377(15) 1
Unknown5 2156 434 (20)
Last WHO4 clinical stage
1 or 2 7025 1024 (15) 1 1
3 or 4 2682 470 (18) 1.2 (1.1–1.4) 1.3 (1.1–1.6)
No WHO stage in last 12 m5 2356 447 (19)
Last CD4 count
<350 cells/µl 1421 296 (21) 1.8 (1.5–2.2) 2.2 (1.7–2.9)
350+ cells/µl 1741 218 (13) 1 1
No CD4 in last 12 m5 8901 1427 (16)
TB co-infection status
Current TB infection 117 22 (19) 1.3 (0.8–2.2)
No current co-infection 5354 785 (15) 1
TB status unknown5 6590 1134(17)
ART2 regimen
1st line 9818 1516(15) 1
2nd line 66 11 (17) 1.1 (0.6–2.2)
Regimen unknown5 2181 414 (19)
1. The adjusted ORs are those from the ﬁnal model, and include control for clustering by health facility.
2 ART = antiretroviral therapy.
3. Median time on ART in undetectable group was 2.7 years (95% CI 1.4–4.4).
4. WHO = World Health Organisation.
5. ‘Unknown’ categories are included when >1% of values are missing. Having a missing value for time on ART, WHO Clinical Stage, last C4 count, TB
co-infection status or ART regimen was associated with increased likelihood of detectable VL. These patients were excluded from the ﬁnal regression
model (see methods and S1 Table).
doi:10.1371/journal.pone.0116144.t001
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On bivariate analysis, patients younger than 20, those with VL>1000 at initial test, and
those with CD4 count<350 cells/ml were more likely to show virologic failure at retesting
(p<0.01 in each case). Gender, WHO clinical stage, TB co-infection status, time on ART, type
of facility and ART regimen were not associated with likelihood of virologic failure. Patients
who had a detectable VL at their early adherence test (at six months) appeared as likely to re-
suppress as those who were detectable at routine annual monitoring. There was no difference
in re-suppression rates between those who underwent EAC and those who did not. Restricting
analysis to patients with a first detectable VL of over 1000 had no effect on these findings.
In the final multivariate regression model, the factors associated with virologic failure were:
being a child or an adolescent, having an initial VL between 1000 and 50,000 copies/ml and re-
cent CD4<350 cells/ml. Crude and Adjusted Odds Ratios are shown in Table 2.
Discussion
This programmatic study demonstrated that children and adolescents on ART were more like-
ly to have raised VLs, and less likely to achieve viral suppression at retesting when compared
with the adult cohort. Receiving EAC did not appear to increase the likelihood of viral suppres-
sion, relative to receiving a detectable VL result from the health worker.
Overall, 84% of patients in the cohort had an undetectable VL, and of those with detectable
VLs, 54% resuppressed following planned adherence counselling. Likelihood of viral detectabil-
ity increased with time on ART and advanced disease; virologic failure was more likely in
advanced disease (as indicated by CD4 cell count). This is consistent with other studies, and
suggests that these groups are more likely to have resistance mutations.[8, 10]
Children and adolescents
Children and adolescents were significantly more likely to have a detectable VL, and less likely
to re-suppress at retesting. This is consistent with the limited available evidence on VL moni-
toring in children, and evokes the specific barriers to adherence faced by children and adoles-
cents, that are unlikely to be addressed successfully through counselling.[4, 11] Due to the
limited availability of paediatric fixed-dose ARV formulations, children in Swaziland are often
required to take a number of tablets each day, which may well contribute to this poorer adher-
ence. Furthermore, treatment support models based primarily on counselling the caregiver
may be poorly adapted to the needs of younger people. In contrast, programmes which make
use of social workers, peer support and training on paediatric disclosure have reported better
virological outcomes in children.[12] Since levels of paediatric drug resistance in Swaziland are
relatively low [9] care must be taken to exclude ongoing adherence problems when applying
the WHO 2013 algorithm to children and adolescents, to avoid inappropriate changes to sec-
ond line therapy. Where feasible, more regular VL measurements and use of genotyping should
be considered in these cases.
Enhanced adherence counselling
In our study patients with raised VLs who received EAC by lay counsellors were no more likely
to have a subsequent suppressed VL than those who did not receive counselling. Although fac-
tors such as age and sex were controlled for in the analysis, there may be other factors that
could explain why patients who did not undergo counselling tended also to suppress their VL
at re-testing. For example, these patients may be more empowered (or employed) and may
have chosen not to attend counselling, instead managing to improve their adherence autono-
mously; likewise the health worker may have made more effort to persuade those most in need
of counselling to attend counselling, which may explain the poorer than expected virologic
Predictors of Viral Suppression in People with HIV on ART in Swaziland
PLOS ONE | DOI:10.1371/journal.pone.0116144 February 19, 2015 8 / 12
Table 2. Factors associated with viral re-suppression (viral load<100 copies/ml, or 2 log reduction) after planned adherence counselling in
patients with detectable viral load on antiretroviral therapy in Swaziland, 2012–2013.
Total n Re-suppressed n (%) Odds Ratio OR (95% CI) Adj. Odds Ratio1 AOR (95% CI)
Gender
Male 327 170 (52) 0.9 (0.7–1.2)
Female 507 280 (55) 1
Age group
<10yrs (children) 72 27 (38) 0.4 (0.3–0.7) 0.2 (0.1–0.7)
10–19yrs (adolescents) 98 33 (34) 0.4 (0.2–0.6) 0.3 (0.2–0.8)
20+ (adults) 661 389 (59) 1 1
First viral load (copies/ml)
101–1000 170 124 (73) 1 1
1001–5000 176 92 (52) 0.4 (0.3–0.6) 0.3 (0.1–0.5)
5001–50000 291 132 (45) 0.3 (0.2–0.5) 0.3 (0.1–0.7)
over 50,000 198 103 (52) 0.4 (0.3–0.6) 0.4 (0.2–1.1)
Type of facility
Secondary facility 381 214 (56) 1.2 (0.9–1.5)
Primary care clinic 454 237 (52) 1
Time on ART2
Median time in years (IQR) 2.9 (1.6–4.8) 2.8 (1.5–4.6)3 0.9 (0.9–1.0)
< 9 months (early adherence) tests) 38 21 (55) 1.0 (0.5–1.9)
> 9 months (routine annual) 674 374 (56) 1
Unknown time on ART5 123 56 (46)
Last WHO4 clinical stage
1 or 2 472 263 (56) 1
3 or 4 236 131 (56) 1.0 (0.7–1.4)
No WHO stage in last 12 m5 127 57 (45)
Last CD4 count
<350 cells/µl 146 71 (49) 0.5 (0.3–0.8) 0.4 (0.2–0.7)
350+ cells/µl 113 75 (66) 1 1
No CD4 in last 12m5 576 305 (53)
TB co-infection status
Current TB infection 7 4 (57) 1.2 (0.3–5.4)
No current co-infection 393 208 (53) 1
TB status unknown5 435 239 (55)
ART2 regimen
1st line 707 393 (56) 1
2nd line 5 3 (60) 1.2 (0.2–7.2)
Unknown regimen5 123 55 (45)
Enhanced adherence counselling
No counselling 35 22 (63) 1
1–3 counselling sessions 145 70 (48) 0.5 (0.2–1.1)
No information collected5 655 359 (55)
1. The adjusted ORs are those from the ﬁnal model, and include control for clustering by health facility.
2 ART = antiretroviral therapy.
3. Median time on ART in undetectable group was 3.2 years (95% CI 18–4.9).
4. WHO = World Health Organisation.
5. ‘Unknown’ categories are included when >1% of values are missing. On regression analysis, no association was seen between likelihood of re-
suppression and having unknown missing value for time on ART, WHO Clinical Stage, last C4 count, TB co-infection status or ART regimen.
doi:10.1371/journal.pone.0116144.t002
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outcomes in the counselling group Secondly, the lack of apparent difference between the
counselling and non-counselling groups may reflect a weakness in counselling training and su-
pervision. Thirdly, whilst the WHO recommends an adherence intervention for patients with
detectable VL, it does not specify what form that intervention should take. We must recognise
that the act (by the health worker) of explaining to a patient that their VL is detectable
constitutes an intervention in itself; indeed, we can assume that all retested patients were noti-
fied of their initial result, even if they did not subsequently receive counselling. If it is this inter-
vention that results in re-suppression, then efforts must focus on improving ‘treatment
literacy’ amongst patients on ART, including awareness of the role and importance of VL test-
ing. Finally, viral resistance was not measured in this study, and thus the possibility that rates
of resistance were higher in the counselling group cannot be excluded.
Virologic ‘blips’
Patients with an initial low detectable VL (<1000copies/ml) were more likely to resuppress;
this may reflect a ‘return to mean’ phenomenon, or virologic ‘blips’, rather than indications of
poor adherence or resistance.[13] Raising the threshold for EAC and retesting to 1000 copies/
ml could avoid unnecessary use of counselling and laboratory resources in this group.
However, this must be balanced with the evidence that chronic low-level viraemia
(100–1000copies/ml) is associated with poorer health outcomes.[14]
Missing data
Our final database had a substantial amount of missing data, predominantly where we were
unable to link the VL laboratory records with the national ART database. These patients ap-
peared more likely to have detectable VLs. It is possible that they started ART prior to the im-
plementation of the electronic register (which explains why we could not link their laboratory
records), and have thus been on ART for longer, with consequent higher likelihood of treat-
ment failure due to acquired resistance. If this is the case, our analysis may underestimate the
effect of time on ART on likelihood of viral detectability. However, we also noticed that many
of these patients came from the same few health facilities, which could suggest that these facili-
ties are delivering poorer quality of care. We controlled for clustering by health facility in order
to minimise the impact this would have on our estimations.
Strengths and limitations
This study has several strengths: the sample was relatively large and included a large number of
children, with good overall testing coverage of the ART cohort. For the planned adherence
counselling, we verified if counselling was actually received, which has not been reported in
other similar studies to our knowledge. STROBE guidelines were followed in the reporting of
the study.[15]
However, since the study uses routine programme data, conclusions are limited by issues of
data quality and missing values. Where possible we have controlled for this in the analysis. For
the re-suppression analysis, 40% of the ‘detectable’ patients failed to undergo retesting during
the study period; it is possible that this 40% are more likely to remain detectable than the 60%
who successfully underwent retesting. Since the Swaziland VL programme is new, this analysis
included patients having their first VL test at six months, as well as patients having a first test
after many years on ART; once the programme is well established, it will be possible to com-
pare these early adherence tests results with the results from patients undergoing annual moni-
toring who are known to have been virally suppressed at previous VL monitoring. Due to
operational constraints we only collected data on counselling for a sub-sample of the detectable
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cohort; but since rates of re-suppression in this sub-sample were similar to those in the whole
detectable cohort, this is unlikely to affect the overall results. Finally, this study does not look at
clinical outcomes or make use of viral genotyping of patients with virologic failure to confirm
the presence of resistance mutations. Whilst this would certainly be of programmatic interest,
it would require a prospective cohort study and is outside the scope of this descriptive analysis.
Conclusions and Recommendations
VL monitoring has the potential to improve ART treatment support, but clinicians should take
into account the patient’s age and disease status when interpreting the VL results, and should
make efforts to exclude ongoing adherence problems before considering second line therapy.
This is especially the case in young people, as the adherence barriers they face may not be ame-
nable to adult-oriented counselling; tailored treatment support with more regular VL monitor-
ing may be helpful in this group.
For patients with elevated VLs, the act of communicating (and explaining) their result,
which can be seen as improving ‘treatment literacy’, may be a key element of any adherence in-
tervention. Further operational research should aim to define the other components of effective
adherence support for patients with detectable VL.
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